Peptibodies: A flexible alternative format to antibodies (Q33402480)

26 July 2017

Peptibodies: A flexible alternative format to antibodies (English)

1 reference

26 July 2017

1 reference

Grant Shimamoto

1

1 reference

26 July 2017

Colin Gegg

series ordinal

2

1 reference

26 July 2017

Tom Boone

series ordinal

3

1 reference

26 July 2017

Christophe Quéva

series ordinal

4

1 reference

26 July 2017

23 July 2012

1 reference

26 July 2017

Monoclonal Antibodies

1 reference

26 July 2017

4

1 reference

26 July 2017

586-591

1 reference

26 July 2017

5

1 reference

The development of romiplostim for patients with immune thrombocytopenia

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Romiplostim or standard of care in patients with immune thrombocytopenia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Strategies to extend plasma half-lives of recombinant antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Nerve growth factor in rheumatic diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

FcRn: the neonatal Fc receptor comes of age.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Manufacturing of recombinant therapeutic proteins in microbial systems

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Bacteriophage display and discovery of peptide leads for drug development

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3499299

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.21024

AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.21024

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.21024

Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.21024

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22820181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22820181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/MABS.21024

1 reference

26 July 2017

1 reference

26 July 2017

1 reference